UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): September 2, 2025
VYOME HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
| Delaware | | 1-37897 | | 26-1828101 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
Harvard Square, One Mifflin Place, Suite 400 Cambridge, MA | | 02138 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s
telephone number, including area code: (973) 832-8147
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
| Common stock, par value $0.001 per share | | HIND | | The Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events.
As
previously disclosed, on August 15, 2025, Vyome Holdings, Inc. (f/k/a ReShape Lifesciences Inc.) (the “Company”) completed
the previously announced merger pursuant to the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the “Merger
Agreement”), by and among the Company, Raider Lifesciences Inc., a wholly owned subsidiary of the Company (“Merger Sub”),
and Vyome Therapeutics, Inc. (“Vyome”). Pursuant to the Merger Agreement, Merger Sub merged with and into Vyome, with Vyome
surviving the merger as a subsidiary of the Company (the “Merger”). As a result of the Merger, the Company was renamed “Vyome
Holdings, Inc.” and Vyome continued under its name as Vyome Therapeutics, Inc., in each case effective before the open of trading
on August 15, 2025.
This
Current Report on Form 8-K is being filed to provide (1) Vyome’s financial statements for the quarter ended June
30, 2025, filed as Exhibit 99.1 hereto; (2) Vyome’s Management’s Discussion and Analysis of Financial Condition
and Results of Operations for the quarter ended June 30, 2025, filed as Exhibit 99.2 hereto; and (3) unaudited pro forma condensed
combined financial statements giving effect to the Merger, filed as Exhibit 99.3 hereto; so that such information is incorporated
by reference into the Company’s shelf registration statement on Form S-3 (File No. 333-287168) filed with the Securities
and Exchange Commission on May 9, 2025 under the Securities Act of 1933, as amended.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit No. |
|
Description |
| 99.1 |
|
Financial Statements of Vyome for the quarter ended June 30, 2025 |
| 99.2 |
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations of Vyome for the quarter ended June 30, 2025 |
| 99.3 |
|
Unaudited Pro Forma Condensed Combined Financial Statements |
| 104 |
|
Cover Page Interactive Data File (embedded within the
Inline XBRL document). |
| * |
Schedules have been omitted
pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted
schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2
of the Exchange Act for any schedule so furnished. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
VYOME HOLDINGS, INC. |
| |
|
| September 2, 2025 |
By: |
/s/
Venkat Nelabhotla |
| |
Name: |
Venkat Nelabhotla |
| |
Title: |
President & Chief Executive Officer |
2
